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Summary
 
Rheumatoid arthritis (RA) is an autoimmune disease that is strongly associated with the ex-
 
pression of several HLA-DR haplotypes, including DR1 (DRB1
 
*
 
0101). Although the antigen
that initiates RA remains elusive, it has been shown that many patients have autoimmunity di-
rected to type II collagen (CII). To test the hypothesis that HLA-DR1 is capable of mediating
an immune response to CII, we have generated transgenic mice expressing chimeric (human/
mouse) HLA-DR1. When the DR1 transgenic mice were immunized with human CII (hCII),
they developed a severe autoimmune arthritis, evidenced by severe swelling and erythema of
the limbs and marked inflammation and erosion of articular joints. The development of the au-
toimmune arthritis was accompanied by strong DR1-restricted T and B cell responses to hCII.
The T cell response was focused on a dominant determinant contained within CII(259–273)
from which an eight amino acid core was defined. The B cell response was characterized by
high titers of antibody specific for hCII, and a high degree of cross-reactivity with murine type
II collagen. These data demonstrate that HLA-DR1 is capable of presenting peptides derived
from hCII, and suggest that this DR1 transgenic model will be useful in the development of
DR1-specific therapies for RA.
 
I
 
t is well established that strong correlations exist between
the expression of specific MHC alleles and increased sus-
ceptibility to certain immune-mediated diseases. Some of
these diseases, such as ankylosing spondylitis, have been
shown to be associated with the expression of a specific
class I allele (HLA-B27), whereas many other diseases are
strongly linked with the expression of certain class II alleles.
One autoimmune disease that has been studied extensively
for its association with class II alleles is rheumatoid arthritis
(RA)
 
1
 
. Many years ago it was noted that a strong correla-
tion existed between the expression of HLA-DR1 or DR4
and an increased risk of developing RA (1–3). We now
know that in most cases, this increased susceptibility is asso-
ciated with the DRB1 locus, and more specifically with the
presence of the DRB1
 
*
 
0101, DRB1
 
*
 
0401, DRB1
 
*
 
0404,
or DRB1
 
*
 
0405 genetic allotypes (4). Sequence analysis of
these alleles revealed that each encodes a similar amino acid
sequence within residues 67–74, termed the shared epitope
(5, 6). The role of this shared epitope has been the focus of
several hypotheses (5–8); however, little is known about
how it affects the function of the DR molecules and con-
fers susceptibility to RA.
Although the etiology of RA remains unsolved, several
antigens have been proposed to be involved in the stimula-
tion of pathogenic T cells in RA. Viral proteins such as
CMV and EBV have been implicated (9, 10), as well as au-
tologous proteins normally expressed in diarthroidial joints.
One autologous protein, type II collagen (CII), has re-
ceived considerable attention as a potential antigen in RA
because of both its ability to induce experimental autoim-
mune arthritis in several animal models (11–13), and the
demonstration of CII-specific immunity in the diseased
synovium and cartilage of RA patients (14–17). Although it
 
1
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 CII, type II collagen; CIA, collagen-induced
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has not been proven that autoimmunity to CII initiates
RA, it seems clear that at least some of the autoimmunity
in RA is directed towards CII. The difficulty, however, has
been in determining the relationship between immunity to
CII and the role of the class II alleles that confer suscepti-
bility to RA.
One approach to analyzing the role of the HLA-DR
molecules in RA is to establish them as transgenes in ani-
mals. Using transgene models, antigens proposed to be rec-
ognized by DR-restricted T cells can be tested for their
ability to induce an immune response as well as elicit an
experimental autoimmune disease. In addition, HLA trans-
genic (Tg) mice facilitate the identification of peptides pre-
sented by DR molecules from an antigen in question, espe-
cially from human proteins. Toward these aims, we have
established transgene expression of a chimeric (human/
mouse) HLA-DR1 molecule (DRB1
 
*
 
0101, DRA1
 
*
 
0101)
in the arthritis-resistant B10.M (H-2
 
f
 
) mouse in an attempt
to determine if the DR1 molecule is capable of presenting
peptides derived from human CII (hCII), and if this pre-
sentation would lead to the development of an experimen-
tal autoimmune arthritis. Here we report that this chimeric
DR1 transgene is fully functional as a class II restriction el-
ement in the mouse and strongly confers susceptibility to
an autoimmune, collagen-induced arthritis (CIA) after im-
munization with hCII. In contrast, non-Tg control mice
were totally resistant to arthritis induction and mounted
only a negligible immune response to hCII. The autoim-
mune arthritis that develops in the DR1 Tg mice is accom-
panied by strong T and B cell responses to hCII. Virtually
all of the DR1-restricted T cell responses to hCII are di-
rected to two antigenic determinants, with the core of the
dominant determinant located within CII(263–270). Anti-
bodies produced by DR1 Tg mice after hCII immuniza-
tion bound strongly to both the immunogen, hCII, and the
autoantigen murine CII (mCII). These data indicate that the
DR1 molecule is capable of binding and presenting pep-
tides derived from hCII, supporting the hypothesis that au-
toimmunity to CII plays a role in the pathogenesis of RA.
 
Materials and Methods
 
Animals.
 
(C57BL/6 
 
3
 
 SJL/J)F2 and B10.M/Sn (H-2
 
f
 
) mice
were obtained from Jackson Laboratories (Bar Harbor, ME).
 
Generation of Tg Mice Expressing DR1.
 
Chimeric (human/mouse)
DRB1
 
*
 
0101 constructs were made using the chimeric DRB1
 
*
 
0401
 
b
 
 chain gene construct that has been previously described (18).
To generate the chimeric DRB1
 
*
 
0101 gene construct, the
plasmid containing the chimeric DRB1
 
*
 
0401 
 
b
 
 chain gene was
partially digested with BamHI and completely digested with
EcoRI to remove a gene fragment encompassing exon 2. A PCR
product was obtained by amplification of DRB1
 
*
 
0101 
 
b
 
 chain
cDNA with primers flanking exon 2 of the DRB1
 
*
 
0101 
 
b
 
 chain
(5
 
9
 
-AAC-CGG-ATC-GTT-CTT-GTC-CCC-CCA-GCA-CGT-
TTC-TTG-TGG-CAG-CTT-AAG-T-3
 
9
 
 and 5
 
9
 
-CGG-CCC-
GCC-CCG-GCG-CCG-TGC-TCA-C-3
 
9
 
). Intron/exon splice
junctions along with BamHI and EcoRI cloning sites were ligated
onto this gene fragment by a second PCR using overlapping
primers (5
 
9
 
-GAC-TTG-AAT-TCC-GGA-GGC-GCT-TCT-GTA-
ACC-GGA-TCG-TTC-TTG-TCC-CCC-C-3
 
9
 
 and 5
 
9
 
-GAC-
TTG-GAT-CCG-CCG-CTC-ACA-GGG-CTC-GGC-CCG-
CCC-CGG-CGC-CGT-GC T-C-3
 
9
 
). The resulting 372-bp PCR
product was digested with BamHI and EcoRI and cloned into
the partially digested chimeric 
 
b
 
 chain gene construction de-
scribed above. To generate Tg mice, fertilized (C57BL/6 
 
3
 
 SJL/
J)F2 oocytes were microinjected with an XhoI/NotI DNA frag-
ment containing the chimeric DRB1
 
*
 
0101 
 
b
 
 chain gene along
with a DNA fragment containing the chimeric DRA1
 
*
 
0101 gene
(18). Eight Tg founders were obtained. The founder with the
highest cell surface DR1 expression levels was backcrossed for
three generations with B10.M mice and then intercrossed to fix
the H-2
 
f
 
 locus and DR1 transgenes to homozygosity.
Tg control mice were derived from DR negative litter mates
during the backcross breeding and express only I-A
 
f
 
 from the class
II locus. For these experiments all mice were bred and maintained
at the Veterans Affairs Medical Center of Memphis (Memphis,
TN) in a specific pathogen-free environment, and sentinel mice
were tested routinely for the presence of mouse hepatitis and
Sendai viruses.
 
Collagen Preparation.
 
Native hCII was solubilized from sternal
cartilage harvested from donors 
 
,
 
20 yr of age by limited proteol-
ysis with pepsin and purified by repeated differential salt precipi-
tation as described by Miller (19).
 
Immunizations.
 
6–8-wk-old mice were immunized with hCII
for the induction of arthritis. hCII was dissolved in cold 0.01 M
acetic acid by stirring overnight at 4
 
8
 
C, and emulsified at a 1:1
(vol/vol) ratio with complete Freund’s adjuvant (GIBCO BRL,
Gaithersburg, MD), as previously described (20). Mice were im-
munized subcutaneously at the base of the tail with 100 
 
m
 
g of
hCII. For some experiments, mice were boosted 2–3 wk later
with 100 
 
m
 
g of hCII in incomplete Freund’s adjuvant. Each paw
was evaluated and scored for the degree of inflammation on a
scale of 0–4 (21).
 
Peptide Synthesis.
 
Peptides were synthesized by Fmoc chem-
istry using either an automated peptide synthesizer (model 430;
Applied Biosystems, Foster City, CA), or manually using the
Mimotope cleavable pin technology (Chiron Mimotopes, San
Diego, CA), essentially as described (22, 23). For the Mimotope
synthesis, the active ester Fmoc protecting groups were removed
by treatment with 20% piperidine in dimethyl formamide (DMF;
vol/vol), and after several washes in methanol, the subsequent
Fmoc amino acids were added in a step-wise fashion to generate
15-mer peptides. Hydroxyproline (BACHEM Bioscience Inc.,
Philadelphia, PA) was obtained as a standard Fmoc, necessitating
the use of 1-hydroxybenzotriazole (Calbiochem, La Jolla, CA)
when coupling this amino acid to the peptide chains. Upon com-
pletion of the synthesis, the side groups were deprotected with
TFA and anisole (95:5, vol/vol), and terminal amino groups were
acetylated with acetic anhydride in DMF and triethylamine (2:5:1;
vol/vol/vol). The pins were then washed thoroughly to remove
residual TFA and scavengers, and the peptides were subsequently
cleaved from the pins by overnight incubation in 750 
 
m
 
l of 50
mM Hepes buffer. Selected Mimotope peptides were analyzed
and quantitated by reverse phase HPLC, and all were 
 
.
 
80% pure
and contained 2–4 
 
m
 
g/
 
m
 
l of peptide.
 
Immunofluorescence.
 
Cell surface expression of class II mole-
cules DR1 and I-A
 
f
 
 was evaluated by immunofluorescence and
flow cytometry. Lymphocytes were obtained from either spleens,
lymph nodes, or purified from peripheral blood using Lym-
pholyte M (Accurate Chemical, Westbury, NY). 2 
 
3
 
 10
 
5
 
 mono-
nuclear cells were incubated with a 100 
 
m
 
l of anti-DR antibody
(L243; Becton Dickinson, San Jose, CA) or anti–I-A antibody 
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(10-3.6) conjugated with FITC. The antibody 10-3.6 was puri-
fied from a culture supernatant using protein A affinity chroma-
tography (Sigma Chemical Co., St. Louis, MO). For two-color
immunofluorescence of I-A
 
f
 
 and DR1, anti-DR (L243; Becton
Dickinson) conjugated to PE was used. After a 30 min incubation
on ice, cells were washed several times with PBS containing 0.1%
sodium azide. Fluorescence was analyzed by a flow cytometer (Coul-
ter Profile II; Coulter Electronics, Miami, FL), and all data are
based on a minimum of 5,000 gated cells analyzed.
 
Proliferation Assays.
 
Draining lymph nodes were removed
from animals at 10 d after immunization, disassociated, and
washed in RPMI 1640. Lymphocytes were cultured in 96-well
plates at 4 
 
3
 
 10
 
5
 
/well in either 300 
 
m
 
l of Click’s medium (24)
supplemented with 0.5% mouse serum, or in HL-1 medium
(BioWhitaker, Inc., Walkersville, MD) at 37
 
8
 
C, 5% humidified
CO
 
2
 
 for 4 d. 18 h before the termination of the cultures, 1 
 
m
 
Ci
of [
 
3
 
H]thymidine (Dupont NEN, Boston, MA) was added to
each well. Cells were harvested onto glass fiber filters, and
counted on a Matrix 96 direct ionization 
 
b
 
-counter (Packard
Instrs., Meriden, CT). Proliferation assays using Mimotope syn-
thetic peptides were performed at one well per peptide and 10 
 
m
 
l
of peptide per well. Results were confirmed by replicate experi-
ments, and all data are expressed as decays per minute.
 
T Cell Hybridomas and Antigen Presentation Assays.
 
T cell hy-
bridomas were established by polyethylene glycol (Boehringer
Mannheim, Indianapolis, IN) induced fusion of lymph node cells
with TCR-
 
a
 
2
 
/
 
b
 
2
 
 BW5147 thymoma cells (25, 26). Lymph node
cells were obtained from B10.M-DR1 Tg mice immunized 10 d
previously with hCII emulsified with complete Freund’s adjuvant
and cultured with human 
 
a
 
1(II) for 5 d, followed by IL-2 for 3 d
before fusion. Resulting hybridomas were screened in antigen
presentation assays for their ability to recognize human 
 
a
 
1(II)
chains presented by DR1 and I-A
 
f
 
. Antigen presentation experi-
ments were performed in 96-well microtiter plates in a total vol-
ume of 0.3 ml containing 10
 
5
 
 APCs or 4 
 
3
 
 10
 
5
 
 syngeneic spleen
cells and 10
 
5
 
 T hybridoma cells. The following APCs were used:
L57.23, L cells (L66) transfected with wild-type DRA1
 
*
 
0101 and
DRB1
 
*
 
0101 (27); DRAB 10, MUD45 cells transfected with chi-
meric DR1 constructs as described for DR4 (18); and 43.2.1, a B cell
hybridoma that expresses I-A
 
f
 
 and I-A
 
d
 
. Cell cultures were main-
tained at 37
 
8
 
C in 5% humidified CO
 
2
 
 for 20–24 h, after which
twofold serial dilutions were made for determination of IL-2 ti-
ters. 4,000 HT-2 cells were added to each supernatant dilution,
and after 16–20 h, HT-2 cell viability was evaluated by visual in-
spection and cleavage of MTT (28, 29). IL-2 titers were quanti-
 
fied by the reciprocal of the highest twofold serial dilution main-
taining 90% viability of the HT-2 cells. Results are presented as
units of IL-2 per milliliter of undiluted supernatant as described
by Kappler et al. (30).
 
ELISA.
 
Antibody titers specific for hCII and mCII were de-
termined using a solid phase ELISA as previously described (31).
In brief, microtiter plates were coated with either 500 ng of hCII
or mCII at 4
 
8
 
C overnight. After extensive washing with 0.15 M
saline/0.05% Tween 20, dilutions of sera ranging from 1:4,000 to
1:24,000 in 2% normal goat sera were added to each well and in-
cubated overnight at 4
 
8
 
C. After washing with saline and Tween
20, a goat anti–mouse Ig (1:5,000) was added for 2 h. The plates
were then washed and developed by the addition of 
 
o
 
-phenyl-
diamine (Sigma Chemical Co.). After stopping the reaction with
2.5 N H
 
2
 
SO
 
4
 
, the degree of color development was measured at
490 nm with background absorbance of 650 nm subtracted. Data
are expressed as mean relative units of activity based on a standard
anti-hCII serum. Sera were collected at 6 wk after hCII immuni-
zation, and quantity of specific antibody was measured for each
animal.
 
Histology.
 
Arthritic and nonarthritic limbs were removed at 6
wk after hCII immunization and fixed in 10% buffered (PBS)
formaldehyde, decalcified in 5% formic acid, and embedded in
paraffin. Serial sections (5 
 
m
 
m) of the joints were stained with ei-
ther hematoxylin and eosin, or toluidine blue.
 
Results
 
Production and Characterization of HLA-DR1 Tg Mice.
 
DR1 Tg founders were backcrossed to the CIA nonsuscep-
tible strain B10.M (H-2
 
f
 
), and homozygous DR1, I-A
 
f
 
mice were established and inbred. The DR1 transgene is
expressed in a tissue-specific manner identical to that of the
chimeric DR4 transgene previously described (18). As
shown in Fig. 1, the DR1 transgene is expressed only by
lymphocytes that express I-A
 
f, and all lymphocytes express-
ing I-Af express the chimeric DR1. Based on immunofluo-
rescence intensity, the DR1 molecule is expressed at an
z10-fold higher level than the previously described chi-
meric DR4 transgene, using the same anti-DR fluorescein-
conjugated antibody (L243, data not shown).
Susceptibility of DR1 Tg Mice to CIA. HLA-DR1 Tg mice
were immunized with hCII to determine if expression of
Figure 1. Expression of chi-
meric HLA-DR1 by lympho-
cytes from Tg mice. Two-color
flow cytometry was performed
to analyze the expression of
DR1 and I-Af using mAbs L243
(anti-DR, PE labeled) and 10-
3.6 (anti–I-Af, FITC labeled). In
the DR1 Tg mice, virtually all of
the cells that express I-Af, also
express DR1. (A) Lymphocytes
from Tg DR1 mice express both
I-Af and DR1. (B) Lymphocytes
from non-Tg B10.M mice ex-
pressing only I-Af. Contour plots
are based on 5,000 cells analyzed.1116 Autoimmune Arthritis in HLA-DR1 Transgenic Mice
DR1 confers susceptibility to CIA in the murine model. As
shown in Fig. 2, DR1 Tg mice are highly susceptible to
CIA induced by immunization with hCII. In two separate
experiments (Fig. 2, A and B), the incidence of arthritis was
100 and 88% (n 5 7 and 9 per experimental group, respec-
tively). These mice developed severe arthritis, evidenced
by marked swelling and erythema of the hind and fore
paws. Inflammation in these paws frequently included the
wrist or ankle and extended distally through the limb and
into the digits (Fig. 3), resulting in the majority of arthritic
scores being 3 or 4 (most severe). Both the severity and the
time of development of arthritis were very similar to that
previously described for CIA in the DBA/1 mouse (12,
21). In contrast, non-Tg control mice, I-Af positive, DR1
negative, were totally resistant to hCII-elicited CIA (Fig. 2).
Histological examination of arthritic DR1 joints revealed
a pathology that was also very similar to that previously de-
scribed for CIA in DBA/1 mice (12, 21). As shown in Fig.
4 A, massive infiltrations of inflammatory cells were fre-
quently evident in the articular joints as well as erosions of
articular cartilage surfaces. Additionally, proliferation of the
synovial lining as well as necrosis of the superficial layer of
the synovium were also evident in some of the arthritic
joints (Fig. 4 B).
The susceptibility of the DR1 Tg mice to CIA was ac-
companied by both a strong T cell proliferative response to
hCII (Table 1) and a strong antibody response to both the
immunogen, hCII, and the autoantigen, mCII (Fig. 5). In
both instances, the immune response of the DR1 Tg mice
Figure 2. HLA-DR1 expression confers susceptibility to CIA in DR1
Tg mice. In two separate experiments, mice were immunized subcutane-
ously at the base of the tail with 100 mg of human CII in CFA. (A) Mice
(n 5 7 per group) were boosted with 100 mg of human CII in incomplete
Freund’s adjuvant at 21 d. (B) Mice (n 5 9 per group) were not boosted.
Beginning at 3 wk after immunization, mice were monitored for inflam-
mation of fore and hind paws. j, DR1 Tg mice; d, non-Tg mice.
Figure 3. Development of ar-
thritis in DR1 Tg mice immu-
nized with hCII. (A) Marked
swelling of the tarsal and meta-
tarsal joints, extending from the
ankles through the digits of a
DR1 Tg mouse immunized with
hCII. (B) Normal hind paw of
immunized non-Tg mouse. (C)
Arthritic fore paw from DR1 Tg
mouse. (D) Normal fore paw
from an immunized non-Tg
mouse.1117 Rosloniec et al.
to hCII was considerably stronger than that of the non-Tg
control mice. 10 d after immunization, the T cell prolifera-
tive response of the DR1 Tg mice was .5 times that of the
control mice (Table 1). At the peak of arthritis incidence
(6 wk after hCII immunization) DR1 Tg mice produced
high levels of hCII-specific antibody, whereas the non-Tg
control mice produced only a small amount of hCII-spe-
cific antibody (Fig. 5). Immunization of DR1 Tg mice
with hCII also induced high titers of antibody that recog-
nized the autoantigen, mCII, whereas little or no mCII-
specific antibody was detectable in the serum of non-Tg
control mice (Fig. 5).
Identification of DR1-restricted T Cell Determinants in
hCII. Based on the susceptibility of DR1 Tg mice to
CIA and their T cell proliferative response to hCII, we
proceeded to identify the hCII antigenic determinants
bound and presented to T cells by the DR1 molecule. A
Figure 4. Histopathology of arthritic joints from DR1 Tg mice immu-
nized with hCII. (A) Hematoxylin and eosin stain of sections from an ar-
thritic hind limb joint. Massive infiltration of inflammatory cells (upper
left) and erosion of articular surfaces (lower articular joint) are clearly evi-
dent. (B) Toluidine blue stain of sections from an arthritic hind limb joint.
Staining reveals proliferation of the synovial lining on the left side of the
joint space as well as necrosis of the synovial lining (upper right portion of the
joint). Samples were obtained 6 wk after hCII immunization.
Table 1. T Cell Proliferative Response of DR Tg1 and
Tg2 Mice to hCII
Strain
[3H]Thymidine incorporation
(D DPM)*
Human a1(II) chain
50 mg 25 mg
B10.M DR1 Tg1/1 81,463 6 3,866 58,030 6 319
B10.M Tg2/2 14,906 6 1,993 12,592 6 2,576
*T cell proliferation assays were performed 10 d after immunization
with hCII as described in Materials and Methods. Data are expressed as
D decays per minute (DPM), (experimental 2 control) 6 SEM. Con-
trol stimulations: B10.M DR1 Tg1/1, 1,796 DPM; B10.M Tg2/2,
3,850 DPM.
Figure 5. Detection of antibody
specific for hCII and mCII after
immunization with hCII. Serum
antibody specific for hCII and
mCII was measured using solid
phase ELISA as described in Ma-
terials and Methods. DR1 Tg
mice (solid bars) produced high
levels of antibody specific for
both hCII and mCII in compar-
ison to non-Tg control mice
(open bars). A and B represent in-
dependent experiments and cor-
respond respectively to A and B
in Fig. 2. Sera were collected at
6 wk after immunization, and
quantity of antibody was deter-
mined for individual mice. Data
are expressed as mean relative
units based on a standard anti-
hCII sera. Error bars indicate the
standard error of the mean.
panel of Mimotope peptides, 15 mer overlapping by 12
amino acids, representing the entire length of the hCII
a1(II) chain, was synthesized and tested for their ability to
stimulate hCII-primed T cells from the DR1 Tg mice. Using
this approach, two definitive DR1-restricted T cell deter-
minants were identified (Fig. 6 A). The dominant DR1 de-
terminant was identified by three consecutive peptides, span-
ning amino acid residues 256–276 of hCII, that strongly
stimulated hCII-primed T cells. Identical data were also
obtained by the use of a second DR1 Tg mouse derived from
the SWR strain (data not shown; 32). When these peptides
were aligned (Table 2), a determinant core of hCII(262–
270) was deduced. This determinant core was verified and
refined by the use of a second set of Mimotope peptides,
advancing 15 mer with a 14–amino acid overlap (Fig. 7). Only
peptides containing hCII residues 263 (F) through 270 (K)
were capable of stimulating T cell proliferation, thus defin-
ing an 8–amino acid determinant core, hCII(263–270). A
second subdominant, but clearly stimulatory determinant1118 Autoimmune Arthritis in HLA-DR1 Transgenic Mice
was also identified for DR1 (Fig. 6 A). This determinant
was present in three consecutive peptides that encompass
hCII(286–306), again allowing deduction of a 9–amino
acid core, hCII(292–300) (Table 2). None of the other mi-
nor peaks were consistently reproducible in repeat experi-
ments with the possible exception of two very minor de-
terminants lying within peptides 826 through 856, and 976
through 1,006 (Fig. 6 A).
Analysis of hCII T cell determinants bound and pre-
sented by the I-Af molecule, expressed by the non-Tg con-
trol mice, identified a single peptide that stimulated T cells
weakly, but significantly above background (Fig. 6 B). This
peptide lies close to the NH2 terminus of the dominant de-
terminant identified for DR1-restricted T cells (Fig. 6 A),
and lies within hCII(250–264) (Table 2). The fact that this
I-Af determinant is represented in only a single 15-mer pep-
tide is consistent with its weak antigenic capacity for stimu-
lating T cells. This I-Af–restricted determinant is also de-
tected as a single peptide in the Mimotope proliferative
response of DR1 Tg mice (Fig. 6 A), located two Mimo-
tope peptides to the NH2 terminus of the dominant deter-
minant. Since the DR1 Tg mice were derived from back-
crosses to B10.M mice, they also express I-Af. Based on the
T cell responses observed with both human a1(II) chains
(Table 1) and the Mimotope peptides, the stimulatory ca-
pacity of the I-Af determinant for the murine T cells is con-
siderably less than that of the DR1 dominant determinant.
Although the dominant determinant was only present in
the proliferative response of the DR1 Tg T cells, it is possi-
ble that a mixed isotype molecule between chains of the I-Af
and the DR1 molecule might have mediated the T cell re-
sponse to hCII. To address this issue, T cell hybridomas de-
rived from DR1 Tg mice immunized with hCII were
tested for their ability to respond to hCII(249–281) pre-
sented by APCs expressing transfected DR1 molecules. A
representative sample of all the hybridomas tested are
shown in Table 3. None of the T cell hybridomas in our
panel were stimulated when the antigen was presented by
I-Af. However, each was strongly stimulated by the two
DR1 transfected cell lines used, indicating that the T cell
response to the dominant determinant is clearly DR1 re-
stricted. Additionally, as shown in Table 4, the antigen
specificity of these hybridomas is identical to that defined in
the T cell proliferative assay (Fig. 6 and Table 2). Interest-
ingly, optimal stimulation of the T cell hybridomas in vitro
did not require that the peptide be presented by the chi-
meric form of DR1 (Table 3). Each DR1-restricted T cell
Figure 6. Identification of the hCII immun-
odominant T cell determinants recognized by T
cells from DR1 Tg and non-Tg mice. Mice were
immunized with hCII and tested for their ability to
respond to a panel of Mimotope peptides, 15 mer
overlapping by 12 amino acids, spanning the entire
length of the human a1(II) chain. The abscissa in-
dicates the NH2-terminal residue number of the
synthetic peptide. 10 ml of synthetic peptide (10–40
mg) was used in each proliferation assay. The data
are expressed as DPM; (A) DR1 Tg mice, (B) non-
Tg mice. Mean [3H]thymidine incorporation in the
absence of antigen was 3,696 DPM in A and 2,095
DPM in B. Data are representative of three inde-
pendent experiments.
Figure 7. Identification of the core of the immunodominant determi-
nant. hCII-primed T cells from DR1 Tg mice were tested for their ability
to recognize a panel of Mimotope peptides, 15 mer, overlapping by 14
amino acids. Underlined residues indicate the deduced core of the T cell
determinant. Data are expressed as DPM. T cell proliferation in the ab-
sence of antigen was 1,247 DPM.1119 Rosloniec et al.
hybridoma examined responded equally well to the CII
peptide presented by the chimeric DR1 molecule as with
the wild-type DR1 molecule.
Discussion
The relationship between the expression of specific
HLA-DR alleles and the predisposition to developing RA
has been the subject of numerous hypotheses aimed at de-
termining the functional role of these class II molecules in
RA. One hypothesis proposes that the DR molecules that
confer susceptibility to RA do so by means of the shared
epitope located in the a-helical region of the b chain (6,
33, 34) and that this shared epitope selects pathogenic T cells
that promote the autoimmune response (8). Initial stimula-
tion of these pathogenic T cells would still be dependent
on the presence of an antigenic peptide of unknown origin,
bound and presented by the DR molecule. Recently,
Zanelli et al. proposed an alternate hypothesis for the role
of the shared epitope in conferring susceptibility to RA (7).
Based on linkages between specific DRB and DQB genes,
they have proposed that an extended DQ/DR haplotype
confers susceptibility to RA, and that the polymorphisms of
the DRB1 chain control this susceptibility (35). The basis
for this protection/susceptibility is proposed to be through
the presentation of a peptide derived from the shared
epitope region of the DRB1 molecule. If derived from a
nonsusceptible DR allele, this peptide binds tightly to an
HLA-DQ8 molecule and the DQ8–peptide complex alters
the T cell repertoire, resulting in protection from RA (35).
In contrast, when this peptide is derived from DR alleles as-
sociated with increased susceptibility to RA, it binds poorly
to the DQ molecule, thus allowing the potentially autore-
active T cells to survive. In contrast to the shared epitope
hypothesis described above, this hypothesis predicts that
the DQ molecule, and not the DR molecule, mediates the
autoimmune response in RA, and indeed Tg HLA-DQ8
mice are susceptible to CIA elicited by bovine CII (36).
Although it appears that the HLA-DQ8 molecule can
participate in the autoimmune response in RA, the data we
have presented here indicates that the DR1 molecule may also
participate as an antigen presenter to pathogenic T cells. Our
studies demonstrate that the DR1 molecule is fully capable
of binding and presenting peptides derived from the pro-
cessing of hCII, and that in a DR1 Tg mouse model, the
DR1-restricted anti-hCII response leads to the develop-
ment of a severe autoimmune arthritis. Although these data
do not address the issue of what initiates the autoimmune
response that leads to the development of RA, hCII is ap-
pealing as one of the antigens involved in the autoimmune
response in RA for several reasons. First, autoimmune ar-
thritis models of RA have been described for several species
including mouse (12), rat (13), and monkey (11, 37), all as
a result of immunization with CII. Second, CII is a major
component of articular cartilage, the site of inflammation in
RA, and anti-CII antibodies have been eluted from a high
percentage of RA cartilages (17). Lastly, several studies
have demonstrated the existence of T (15) or B cell (16,
38–40) immunity to CII in RA patients. Consequently,
these data suggest that at least some of the autoimmune re-
sponse in RA is DR-restricted and that these anti-CII re-
sponses may be mediated directly by the DR1 molecule
presenting an hCII peptide to T cells.
The DR transgenes used in these studies encode chi-
meric molecules in which the second domains of the DR1
chains were replaced with corresponding domains from the
Table 2.  Human CII Determinants Recognized by T Cells from B10.M and B10.M-DR1 Mice
T cell determinant Peptide* Peptide sequence‡ T cell stimulation§
hCII (247–261) GPLGPKGQTGEBGIA 2
B10.M determinant hCII (250–264) GPKGQTGEBGIAGFK 1
hCII (253–267) GQTGEBGIAGFKGEQ 2
B10.M-DR1 hCII (256–270) GEBGIAGFKGEQGPK 1
Dominant determinant hCII (259–273) GIAGFKGEQGPKGEB 1
hCII (262–276) GFKGEQGPKGEBGPA 1
hCII (265–279) GEQGPKGEBGPAGPQ 2
hCII (283–297) GPAGEEGKRGARGEB 2
B10.M-DR1 hCII (286–300) GEEGKRGARGEBGGV 1
Subdominant hCII (289–303) GKRGARGEBGGVGPI 1
determinant hCII (292–306) GARGEBGGVGPIGPB 1
hCII (295–309) GEBGGVGPIGPBGER 2
*Mimotope synthetic peptides. Sequence numbers are based on assigning the first amino acid of the human a1(II) chain as residue number 1.
‡Synthetic peptides are aligned according to sequence overlap used in the Mimotope analysis. Alignment allows for deduction of determinant core
(underlined text) when more than one peptide is stimulatory for T cells. Amino acids are represented by single letter code with B denoting hydroxy-
proline.
§Stimulation data summarized from T cell proliferation data in Fig. 6.1120 Autoimmune Arthritis in HLA-DR1 Transgenic Mice
murine I-E chains, thereby enhancing the interaction of
murine CD4 with the DR1 molecule. This was done to
enable murine CD4 interaction with the DR1 molecule
since, at least for some antigens, there appears to be a spe-
cies barrier to the interaction of murine CD4 with human
class II (41, 42). Surprisingly, all of the T cell hybridomas
produced in these studies using the chimeric DR1 mice are
not dependent on the presence of the chimeric second do-
main for stimulation. The hybridomas are stimulated equally
well with CII peptides presented by the chimeric DR1 or
by the wild-type DR1, expressed either as a transfectant or
on EBV-transformed B cells. Regardless of whether this in-
dicates that murine CD4 interacts weakly with DR1 or
that the immune response to CII in the DR1 Tg mice is
CD4 independent, it appears that all of these hybridomas
express high affinity TCR. This conclusion is supported by
the fact that they respond very well to as little as 100 nM
concentrations of antigen (data not shown). Whether this is
due to the levels of transgene expression or the characteris-
tics of hCII as an antigen is not clear, but similar sensitivi-
ties to antigen stimulation have been reported for a chi-
meric DR4 transgene (18).
It is interesting to note that most of the dominant T cell
determinants that have been described for CII, regardless of
the MHC restriction, are clustered within a small region of
the CII molecule. The dominant determinant, CII(260–
267), for I-Aq, one of the natural murine susceptibility alleles,
overlaps with the DR1 determinant, CII(263–270), al-
though they clearly use different class II binding motifs
(43). The I-Af dominant peptide identified in these studies,
Table 3.  The Response of DR1-Tg1 T Cells to hCII Is Restricted by HLA-DR1
T cell hybridoma
APC*
Chimeric DR1 DR1 I-Af
1 Antigen‡ 2 Antigen 1 Antigen 2 Antigen 1 Antigen
DR1hCII-2.0 .2,560 –§ .2,560 – –
DR1hCII-3.0 .2,560 – .2,560 – –
DR1hCII-14.0 .2,560 – .2,560 – –
DR1hCII-16.0 2,560 – .2,560 – –
DR1hCII-19.0 2,560 – .2,560 – –
DR1hCII-22.0 .2,560 – .2,560 – –
*APCs: DRAB10, transfected cells that express the chimeric DR1; L57, transfected L cells expressing wild-type DR1; and, the B cell hybridoma 43.2.1 that
expresses I-Af.
‡Antigen presentation assay performed as described in Materials and Methods. hCII(249–281) was used as antigen at 150 mg/ml final concentration.
§2, less than 20 U/ml of IL-2 produced.
Table 4. DR1-restricted T Cell Hybridomas Are Specific for the hCII(262–270) Core Determinant
T cell hybridoma
IL-2*
Human CII Mimotope Peptides‡
CII(250–264) CII(253–267) CII(256–270) CII(259–273) CII(262–276) CII(265–279)
DR1hCII-2 –§ – 2,560 2,560 1,280 –
DR1hCII-3 – – 2,560 2,560 2,560 –
DR1hCII-5 – – 640 1,280 1,280 –
DR1hCII-14 – – 1,280 2,560 1,280 –
DR1hCII-19 – – 2,560 .2,560 640 –
*Production of IL-2 was measured as an indicator of T cell hybridoma stimulation in an antigen presentation assay using DR1-expressing APCs, (cell
line L57). After 24 h of culture, supernatants were collected and tested for the presence of IL-2–dependent cell line HT-2, as described in Materials
and Methods. Data are expressed as units of IL-2 per milliliter.
‡Peptides were derived from the same Mimotope peptide synthesis used in Fig. 6.
§–, ,20 U/ml of IL-2 produced.1121 Rosloniec et al.
CII(250–264) also overlaps with the DR1 and I-Aq deter-
minants, but again is clearly different. Similarly we have
also identified a subdominant I-Aq T cell determinant in the
same region as the DR1 subdominant determinant (Roslo-
niec, E., and D. Brand, unpublished observations). Why
this should be is not clear, and may be more representative
of the primary structure of the collagen molecule itself.
Since these determinants are all derived from the a-helical
portion of CII, they all have a repetitive primary amino
acid sequence of Gly-X-Y, where X and Y are frequently
hydrophobic residues. Since Gly has no side chain with which
to interact with a binding pocket within the I-Aq molecule
(or TCR), the number of potential antigenic peptides con-
tained in a Gly-rich protein would likely be lower than the
number of antigenic peptides in a noncollagenous protein.
Indeed, given its size (.1,000 amino acids), very few anti-
genic peptides have been identified in CII, regardless of the
class II molecule in question. It would appear that either
this area of the collagen molecule contains amino acids fre-
quently used by class II binding motifs, or the diversity of
amino acids within this region of CII is much greater than
the rest of this highly repetitive molecule. Finally, the core
of the T cell determinant identified for DR1, CII(263–
270), appears to be identical to that described for DR4
(DRB1*0401) and bovine CII (44). If this similarity in pep-
tide binding motifs occurs among all of the DR susceptibil-
ity alleles, it may be possible to construct an analogue pep-
tide that effectively interferes with many, if not all, of these
susceptibility alleles, thus simplifying an immunotherapeu-
tic approach to RA.
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